BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 57.60

Change

0.00 (0.00)%

Market Cap

USD 127.99B

Volume

6.67M

Avg Analyst Target

USD 68.67 (+19.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Address: 430 East 29th Street, New York, NY, United States, 10016

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

N/A

USD430.99B 24.47 15.42
PFE Pfizer Inc

N/A

USD241.98B 18.43 12.25
LLY Eli Lilly and Company

N/A

USD233.17B 36.65 27.44
MRK Merck & Co. Inc

N/A

USD205.42B 36.95 17.69
ABBV AbbVie Inc

N/A

USD192.87B 29.43 15.42
NVS Novartis AG

N/A

USD189.94B 21.52 11.81
GSK GlaxoSmithKline plc

N/A

USD100.06B 16.60 11.89
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing BMY

Symbol Name Weight Mer Price(Change) Market Cap
GBF iShares Government/Credit.. 0.00 % 0.20 %

N/A

USD0.16B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.03B
UC86:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.33B
UC97:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.20 %

N/A

USD0.27B
UC98:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.20 %

N/A

USD0.27B
USMV:LSE Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
XGLF:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.65 %

N/A

USD0.03B
XMAF:LSE Xtrackers - MSCI Africa T.. 0.00 % 0.65 %

N/A

USD0.04B
XSFD:LSE Xtrackers - S&P Select Fr.. 0.00 % 0.95 %

N/A

USD0.10B
XSFR:LSE Xtrackers - S&P Select Fr.. 0.00 % 0.95 %

N/A

USD0.10B
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

N/A

N/A
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

N/A

USD0.09B
ETLI:XETRA Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.04B
SPY1:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

N/A

USD0.20B
UET0:XETRA UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

N/A

USD0.51B
VMUS:XETRA VanEck Vectors ETFs N.V. .. 0.00 % 0.00 %

N/A

USD0.01B
XGLF:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.65 %

N/A

USD0.03B
XMKA:XETRA Xtrackers - MSCI Africa T.. 0.00 % 0.65 %

N/A

USD0.04B
ZGEN:CA BMO MSCI Genomic Innovati.. 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
UC85:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.08B
UC82:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.04B
IBDP iShares iBonds Dec 2024 T.. 0.00 % 0.10 %

N/A

USD1.43B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

USD0.33B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

USD0.38B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

N/A

USD0.05B
PPH VanEck Vectors ETF Trust .. 0.00 % 0.35 %

N/A

USD0.23B
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

N/A

USD1.19B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.38 %

N/A

USD0.23B
ZLU:CA BMO Low Volatility US Equ.. 0.00 % 0.33 %

N/A

USD1.77B
HUL:CA Harvest US Equity Plus In.. 0.00 % 2.58 %

N/A

USD7.80M
UC76:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.09B
PRP:CA Purpose Conservative Inco.. 0.00 % 0.69 %

N/A

USD2.09M
BVAL Brand Value ETF 0.00 % 0.65 %

N/A

USD9.33M
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

N/A

USD0.26B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
QUIG:CA Mackenzie US Investment G.. 0.00 % 0.17 %

N/A

USD0.39B
SPXB ProShares S&P 500 Bond ET.. 0.00 % 0.15 %

N/A

USD0.04B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
HUL-U:CA Harvest US Equity Plus In.. 0.00 % 2.58 %

N/A

N/A
BSUS:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.25 %

N/A

USD0.11B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.14% 25% F 15% F
Dividend Return 2.37% 38% F 51% F
Total Return -4.77% 25% F 16% F
Trailing 12 Months  
Capital Gain -4.21% 13% F 12% F
Dividend Return 3.26% 50% F 51% F
Total Return -0.95% 13% F 13% F
Trailing 5 Years  
Capital Gain 16.25% 25% F 44% F
Dividend Return 17.28% 50% F 62% D-
Total Return 33.52% 38% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 4.49% 38% F 45% F
Dividend Return 3.04% 50% F 65% D
Total Return 7.54% 38% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 17.43% 50% F 65% D
Risk Adjusted Return 43.25% 25% F 48% F
Market Capitalization 127.99B 25% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 194.50 13% F 5% F
Price/Book Ratio 3.44 88% B+ 30% F
Price / Cash Flow Ratio 9.11 100% A+ 48% F
EV/EBITDA 19.86 25% F 28% F
Management Effectiveness  
Return on Equity -11.76% 25% F 20% F
Return on Invested Capital 0.06% 13% F 30% F
Return on Assets 4.31% 13% F 68% D+
Debt to Equity Ratio 127.60% 38% F 29% F
Technical Ratios  
Short Ratio 1.96 75% C 54% F
Short Percent 0.90% 25% F 80% B-
Beta 0.63 50% F 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector